Recent Progress of CDK4/6 Inhibitors’ Current Practice in Breast Cancer

Researchers evaluate the utilization strategies of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) across various subpopulations of breast cancer and explore potential therapeutic avenues following disease progression during application of CDK4/6i therapy.